Skip to main content

Table 1 Multivariate analysis based on PLADP tri-classification

From: An optimal window of platelet reactivity by LTA assay for patients undergoing percutaneous coronary intervention

One-year outcome

PLADP

Normal responder*

n = 506

HOPR

n = 521

LOPR

n = 682

n(%)

n(%)

HR(95%CI)

P

n(%)

HR(95%CI)

P

Net adverse clinical events

85 (16.8)

103 (19.8)

1.19 (0.89,1.61)

0.247

175 (25.7)

1.64 (1.25,2.14)

0.000

Ischemic events

11 (2.2)

22 (4.2)

1.99 (0.96,4.10)

0.063

12 (1.8)

0.83 (0.37,1.89)

0.660

 Death

5 (1.0)

12 (2.3)

2.34 (0.82,6.66)

0.111

3 (0.4)

0.45 (0.11,1.88)

0.273

 MI

5 (1.0)

9 (1.7)

1.78 (0.60,5.31)

0.303

6 (0.9)

0.93 (0.28,3.05)

0.903

 ST

5 (1.0)

11 (2.1)

2.23 (0.77,6.43)

0.138

5 (0.7)

0.78 (0.23,2.70)

0.693

 TVR

1 (0.2)

6 (1.2)

5.86 (0.70,48.86)

0.102

4 (0.6)

3.33 (0.37,29.89)

0.282

Bleeding events

80 (15.8)

83 (16.1)

0.99 (0.73,1.36)

0.967

165 (24.2)

1.61 (1.23,2.12)

0.001

 Major + Minor

10 (2.0)

5 (1.0)

0.47 (0.16,1.39)

0.172

17 (2.5)

1.17 (0.53,2.60)

0.701

 Minimal

70 (13.8)

78 (15.1)

1.09 (0.78,1.52)

0.603

148 (21.7)

1.59 (1.19,2.13)

0.002

  1. Risk factors included in the analysis of net clinical outcome: Sex, age, BMI, Smoking, Hypertension, Diabetes, CABG history, PCI history, Hemoglobin, Platelet count, eGFR, APTT, INR; Risk factors included in the analysis of MACE: Sex, Age, BMI, Smoking, Hypertension, Diabetes, CABG history, PCI history; Risk factors included in the analysis of bleeding: Sex, Age, Hypertension, Diabetes, Hemoglobin, Platelet count, eGFR, INR, APTT
  2. *Normal responder: 25.5% ≤ PLADP < 37.5% (control group); HOPR: PLADP ≥ 37.5%; LOPR: PLADP < 25.5%
  3. PLADP ADP induced platelet aggregation, HOPR high on-treatment platelet reactivity, LOPR low on-treatment platelet reactivity, HR hazard ratio, CI confidence interval, MI myocardial infarction, ST stent thrombosis, TVR target vessel revascularization, BMI body mass index, CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, eGFR estimated glomerular filtration rate, APTT activated partial thromboplastin time, INR international normalized ratio